Skip to content

Freezing of gait and the levodopa paradox

Freezing of gait and the levodopa paradox - Freezing of gait and the levodopa paradox

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON50066
Enrollment
75
Registered
2020-06-03
Start date
2020-09-15
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

None listed

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In Tanzania/Brazil, I will include 75 patients with idiopathic Parkinson*s disease who have not been treated with any form of dopaminergic medication (including Mucuna pruriens, which is a tropical legume native to Africa, rich of levodopa). In the Netherlands, I will include 75 patients who have received levodopa-treatment (patients will be matched for disease duration, age and gender). In both cohorts, patients should have a disease duration of at least 5 years, because freezing is rare for patients with a shorter disease duration.

Exclusion criteria

Exclusion criteria: Exclusion criteria include significant co-morbidity limiting the interpretation of ambulation and inability to walk unaided.

Design outcomes

Primary

MeasureTime frame
The presence and severity of freezing of gait will be assessed subjectively using the New-Freezing of gait Questionnaire. Moreover, the presence of freezing of gait will be objectified using the timed-up-and-go test, and four rapid 360-degrees turns in both directions.

Secondary

MeasureTime frame
Phenotype of freezing of gait.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)